SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kdd999 who wrote (7932)10/21/2009 9:18:58 AM
From: idahoranch1   of 63324
 
Thanks KDD, some posters just post a link to a 30 minute presentation and let the reader have to listen to all of it to try to catch a 30 second portion, which most simply won't do. I for one appreciate your breaking it out for us.

What the very negative, and concerted effort at that, articles and new coverage initiated with a sell rating really focus on is the lack of statistical significance of UCB's data. They do admit that the trial was not designed to generate P values, and yet they take the limited data that was released and pound on it for lack of "statistical significance". Of course, a phase lll trial IS designed to meet agreed to end points and do it with P values that "prove" the drug indeed gets the results the data indicates. This is generally "5% or less chance the responses could have been by chance"

It doesn't matter if HGSI' "proves with statistical significant" and a good "P" value that Benlysta barely helps the SLE patients, it is the "proof" they are focused on, not the degree of benefit a patient really gets. Right now it is a money game, and there is big money behind HGSI and seems like big money behind those shorting IMMU and all guns our out blazing. I don't think any of them give a rats ass about the patients, they are the pawns.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News